Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00690833 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis
A Phase 4 study, sponsored by Wake Forest University.
- Completed
- Registry status
- Phase 4
- Development phase
- 41
- Enrollment target
NCT00690833 is a Phase 4 study that has completed, run by Wake Forest University. The registered enrollment target is 41 participants.
The verdict
NCT00690833, a Phase 4 study, has completed, sponsored by Wake Forest University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this research study is to better understand how this study drug works when people use it to treat atopic dermatitis. Desonate has been approved by the US Food and Drug Administration (FDA) for atopic dermatitis.
Interventions
- DRUG topical desonide hydrogel 0.05%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00690833
The ClinicalTrials.gov registry entry for NCT00690833 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which topical desonide hydrogel 0.05% is the first listed.
NCT00690833 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00690833 about?
NCT00690833 is a clinical study titled "Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis". The purpose of this research study is to better understand how this study drug works when people use it to treat atopic dermatitis. Desonate has been approved by the US Food and Drug Administration (FDA) for atopic dermatitis.
What is the current status of trial NCT00690833?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 41 participants. The study started on 2007-08. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00690833?
The interventions under investigation include: topical desonide hydrogel 0.05% (DRUG).
Who is sponsoring clinical trial NCT00690833?
This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.